Pharmaceutical

Pharmaceutical major Lupin has achieved a significant milestone by securing approval from the U.S. Food and Drug Administration (USFDA) for its generic version of a widely used HIV treatment. This regulatory clearance underscores Lupin’s growing footprint in the U.S. market, offering an affordable alternative to branded antiretroviral therapies. The approval is expected to strengthen the company’s revenue streams, expand patient access to critical medications, and enhance its position in the competitive generics landscape.

Global private equity firm Advent International has divested its stake in Cohance Lifesciences, generating proceeds of Rs 3,094 crore. The transaction reflects strong investor confidence in India’s pharmaceutical and life sciences sector, which continues to attract both domestic and international capital. Analysts note that the exit underscores Cohance’s robust operational performance, strategic positioning, and growth trajectory. The sale is expected to enable Advent to realize returns while providing liquidity for reinvestment.

Dr. Reddy’s Laboratories has introduced a novel class of treatment in India for acid reflux, launching a Potassium-Competitive Acid Blocker (PCAB). This new therapy represents an advancement over conventional proton pump inhibitors (PPIs), promising faster onset of action, longer duration of relief, and improved patient outcomes. The launch underscores Dr. Reddy’s commitment to innovation in gastroenterology while addressing a widespread health concern that affects millions of Indians.

Caplin Point Laboratories has received approval from the United States Food and Drug Administration (USFDA) for its Milrinone injection, a cardiovascular drug used in the management of heart failure and related conditions. The approval allows the Indian pharmaceutical firm to market the therapy in the U.S., a key market for high-value generic injectables. This milestone strengthens Caplin Point’s presence in the cardiovascular segment while showcasing its ability to meet stringent regulatory standards.

Indian pharmaceutical giant Lupin has secured approval from the United States Food and Drug Administration (USFDA) for its generic Risperidone injection, a widely used treatment for schizophrenia and bipolar disorder. The approval allows Lupin to market the injectable formulation in the U.S., one of the world’s largest pharmaceutical markets. This regulatory milestone strengthens Lupin’s central nervous system (CNS) portfolio, expands its footprint in high-value generics, and demonstrates its capability to meet stringent international compliance standards.

Caplin Point Laboratories has secured approval from the U.S. Food and Drug Administration (USFDA) for its Milrinone Lactate Injection, a critical drug used in treating patients with severe heart failure. The regulatory clearance represents a significant step for the Chennai-based pharmaceutical company as it seeks to expand its footprint in the U.S. generics market.

Natco Pharma has announced the launch of a new generic drug in the United States, strengthening its presence in one of the world’s most lucrative pharmaceutical markets. The move underscores the company’s strategy to enhance global accessibility to affordable medications while diversifying its international portfolio. By introducing this generic alternative, Natco aims to capture market share in a highly competitive landscape dominated by established players.

Welcure Drugs, a company known for its pharmaceutical expertise, has announced plans to establish a dedicated agro-pharma research laboratory. The initiative is aimed at expanding its footprint into agricultural pharmaceuticals, focusing on innovation in crop protection, plant health, and sustainable farming solutions. By merging pharmaceutical know-how with agricultural science, the company intends to address rising concerns about food security and climate-resilient farming practices.

Aurobindo Pharma’s manufacturing facility in China is on the cusp of achieving break-even, signaling a pivotal turnaround for the company’s international operations. The plant, which focuses on active pharmaceutical ingredients (APIs) and finished dosage formulations, has benefited from optimized production processes, stringent cost controls, and growing demand in both domestic and export markets. Analysts note that reaching break-even will enhance Aurobindo’s global competitiveness and support its expansion strategy in Asia.

Aurobindo Pharma, one of India’s leading pharmaceutical manufacturers, announced that its facility in China is expected to achieve break-even in the near term, signaling progress in the company’s global expansion strategy. The plant, which plays a critical role in the supply of key raw materials and intermediates, has been a significant investment aimed at reducing dependency on third-party suppliers.